2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
Juhani Knuuti, William Wijns, Antti Saraste...
https://pubmed.ncbi.nlm.nih.gov/31504439/Actively Recruiting
Led by Seoul National University Bundang Hospital · Updated on 2026-09-02
2758
Participants Needed
1
Research Sites
26 weeks
Total Duration
This clinical trial evaluates treatment strategies for adults aged 19 years and older who have experienced an acute myocardial infarction at least one year prior or have other cardiovascular conditions like peripheral arterial disease. The study compares the use of clopidogrel-based antiplatelet therapy with a combined therapy of aspirin and low-dose rivaroxaban. It aims to determine whether clopidogrel alone is not worse than the combined therapy in preventing cardiac events. Participants will be randomly assigned to one of two groups one receiving combined antiplatelet and anticoagulant therapy with aspirin and low-dose rivaroxaban, and the other receiving clopidogrel-based antiplatelet therapy, with or without aspirin as decided by their doctor. The study follows participants for 36 months to assess the effects of these treatments. Both therapies are given to prevent blood clots after heart and vascular procedures, balancing risks of clotting and bleeding. During the study, participants will undergo regular evaluations including monitoring of cardiac events such as heart attacks and strokes. Researchers will collect data on outcomes including major thrombotic events and the openness of treated blood vessels. Safety and treatment adherence will be observed throughout the 36-month period. The trial aims to provide insight into optimal long-term prevention strategies for patients with heart and vascular disease.
CONDITIONS
Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy
J
Ju Seung Kwun, M.D
C
Chang-Hwan Yoon, M.D Ph.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Seoul National University Bundang Hospital
Lead Sponsor
Korea University Guro Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 36 months
Participants receive either clopidogrel-based antiplatelet therapy with or without aspirin, or combined therapy with aspirin and low-dose rivaroxaban.
Regular visits throughout the 36 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Juhani Knuuti, William Wijns, Antti Saraste...
https://pubmed.ncbi.nlm.nih.gov/31504439/Marco Valgimigli, Héctor Bueno, Robert A Byrne...
https://pubmed.ncbi.nlm.nih.gov/28886622/Victor Aboyans, Jean-Baptiste Ricco, Marie-Louise E L Bartelink...
https://pubmed.ncbi.nlm.nih.gov/28886620/Seoul National University Bundang Hospital
Lead Sponsor
Korea University Guro Hospital
Collaborating Sponsor